12-Month Follow-up for Patients with Sickle Cell Disease in an Ongoing 3-Year, Prospective, Non-Interventional Registry Trial

Abstract 1010▪▪This icon denotes a clinically relevant abstract Sickle cell disease (SCD) is a clinically heterogeneous disease. Patients (pts) may present with severe symptoms in childhood, resulting in early morbidity and mortality, or may be asymptomatic until adulthood. Therapeutic goals include...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2012-11, Vol.120 (21), p.1010-1010
Main Authors: Heeney, Matthew M., Mueller, Brigitta U., Baltz, Brad, Adams-Graves, Patricia, Yang, Elizabeth, Paley, Carole, Esposito, Jason, Vichinsky, Elliott P.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract 1010▪▪This icon denotes a clinically relevant abstract Sickle cell disease (SCD) is a clinically heterogeneous disease. Patients (pts) may present with severe symptoms in childhood, resulting in early morbidity and mortality, or may be asymptomatic until adulthood. Therapeutic goals include the prevention and treatment of complications across the spectrum of disease. We describe baseline and 12-mo assessments and therapies for pts in an ongoing registry documenting treatment patterns, natural history, and outcomes. Pts ≥2 years old with HbSS, HbS/β-thalassemia, or HbSC were enrolled from 57 US centers and assessed every 6 mos for up to 3 years. Differences between pediatric (age
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V120.21.1010.1010